{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:15Z","timestamp":1786982295541,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T00:00:00Z","timestamp":1466985600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s12185-016-2050-y","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T04:51:29Z","timestamp":1467003089000},"page":"476-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis"],"prefix":"10.1007","volume":"104","author":[{"given":"Moo-Kon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Seop","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong-won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Yeon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,27]]},"reference":[{"key":"2050_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"2050_CR2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","volume":"102","author":"F Cervantes","year":"1998","unstructured":"Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684\u201390.","journal-title":"Br J Haematol"},{"key":"2050_CR3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.1997.782714.x","volume":"97","author":"F Cervantes","year":"1997","unstructured":"Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, et al. Identification of \u2018short-lived\u2019 and \u2018long-lived\u2019 patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635\u201340.","journal-title":"Br J Haematol"},{"key":"2050_CR4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","volume":"98","author":"JT Reilly","year":"1997","unstructured":"Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96\u2013102.","journal-title":"Br J Haematol"},{"key":"2050_CR5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<708::AID-CNCR9>3.0.CO;2-I","volume":"80","author":"HM Kvasnicka","year":"1997","unstructured":"Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:708\u201319.","journal-title":"Cancer"},{"key":"2050_CR6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013\u20138.","journal-title":"Blood"},{"key":"2050_CR7","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"2050_CR8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment). Blood. 2010;115:1703\u20138.","journal-title":"Blood"},{"key":"2050_CR9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"2050_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0268-960X(97)90022-9","volume":"11","author":"JT Reilly","year":"1997","unstructured":"Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11:233\u201342.","journal-title":"Blood Rev"},{"key":"2050_CR11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4065\/78.10.1223","volume":"78","author":"CA Koch","year":"2003","unstructured":"Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003;78:1223\u201333.","journal-title":"Mayo Clin Proc"},{"key":"2050_CR12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117\u201327.","journal-title":"N Engl J Med"},{"key":"2050_CR13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092\u20137.","journal-title":"Blood"},{"key":"2050_CR14","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica"},{"key":"2050_CR15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","volume":"115","author":"K Hussein","year":"2010","unstructured":"Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115:496\u20139.","journal-title":"Blood"},{"key":"2050_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and\u2019leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25:82\u20138.","journal-title":"Leukemia"},{"key":"2050_CR17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361\u201370.","journal-title":"Cancer"},{"key":"2050_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","volume":"61","author":"RA Mesa","year":"1999","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u20131995. Am J Hematol. 1999;61:10\u20135.","journal-title":"Am J Hematol"},{"key":"2050_CR19","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/cncr.22630","volume":"109","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109:2083\u20138.","journal-title":"Cancer"},{"key":"2050_CR20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1988.tb02507.x","volume":"70","author":"G Barosi","year":"1988","unstructured":"Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397\u2013401.","journal-title":"Br J Haematol"},{"key":"2050_CR21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","volume":"75","author":"G Visani","year":"1990","unstructured":"Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4\u20139.","journal-title":"Br J Haematol"},{"key":"2050_CR22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01834368","volume":"68","author":"S Rupoli","year":"1994","unstructured":"Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni MF, et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol. 1994;68:205\u201312.","journal-title":"Ann Hematol"},{"key":"2050_CR23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.1983.tb02069.x","volume":"54","author":"OS Njoku","year":"1983","unstructured":"Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol. 1983;54:79\u201389.","journal-title":"Br J Haematol"},{"key":"2050_CR24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/1097-0142(19850201)55:3<582::AID-CNCR2820550318>3.0.CO;2-O","volume":"55","author":"JB Miller","year":"1985","unstructured":"Miller JB, Testa JR, Lindgren V, Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer. 1985;55:582\u201391.","journal-title":"Cancer"},{"key":"2050_CR25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V72.3.855.bloodjournal723855","volume":"72","author":"JL Demory","year":"1988","unstructured":"Demory JL, Dupriez B, Fenaux P, La\u00ef JL, Beuscart R, Jouet JP, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood. 1988;72:855\u20139.","journal-title":"Blood"},{"key":"2050_CR26","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226\u201333.","journal-title":"Blood"},{"key":"2050_CR27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255\u201365.","journal-title":"N Engl J Med"},{"key":"2050_CR28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","volume":"130","author":"KE Panteli","year":"2005","unstructured":"Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130:709\u201315.","journal-title":"Br J Haematol"},{"key":"2050_CR29","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-09-2836","volume":"16","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res. 2010;16:1988\u201396.","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2050-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2050-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2050-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T20:02:01Z","timestamp":1600804921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2050-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,27]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2050-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,27]]}}}